Phase 3, Randomized, Double-Blind, Placebo-controlled Study of CBT-1 and Paclitaxel/Carboplatin in Patients With Inoperable Non-Small Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Carboplatin; Paclitaxel; Tetrandrine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Sep 2011 Biomarkers information updated
- 28 Sep 2010 Planned end date changed from Dec 2009 to Oct 2010 as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.